5 Sep 2014 07:00
05 September 2014
Instem plc
Notice of Results
Instem plc (AIM: INS.L), a leading provider of IT solutions to the global early development healthcare market, will be announcing its unaudited interim results for the six months ended 30 June 2014 on Wednesday 24th September.
Management will be hosting a presentation for analysts on the day of results at 09:30am at the offices of N+1 Singer, One Bartholomew Lane, London, EC2N 2AX.
If you wish to attend, or require further information, please contact Bob Huxford or Sam Allen at Walbrook PR on 020 7933 8780 or email instem@walbrookpr.com to register.
For further information, please contact:
Instem plc | www.instem.com |
Phil Reason, CEO | Tel: +44 (0) 1785 825 600 |
Nigel Goldsmith, CFO |
|
|
|
N+1 Singer (Nominated Adviser & Broker) | Tel: +44 (0) 20 7496 3000 |
Richard Lindley |
|
Nick Owen |
|
|
|
Walbrook PR Ltd | Tel: 020 7933 8780 or instem@walbrookpr.com |
Bob Huxford | Mob: 07747 635 908 |
Sam Allen | Mob: 07884 664 686 |
About Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are used by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organisations for data-driven decision making leading to safer, more effective products.
Instem's established portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem supports over 400 clients through full service offices in the United States, United Kingdom and China with additional locations in India and a full service distributor based in Japan.